Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC & to Exhibit at Maui Derm...
January 27 2014 - 7:55AM
Business Wire
Presentation Audio and Slides Available Live
and Via Webcast
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an
FDA approved optical diagnostic device that assists dermatologists
in the diagnosis of melanoma, today announced its CEO, Rose Crane,
will present at the SeeThruEquity Winter Microcap Investor
Conference on February 6, 2014 at 9:30 am ET in New York. Ms.
Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and
Diana Garcia Redruello, head of the MelaFind Commercial Team will
be available for one-on-one meetings that day.
Ms. Crane will review the Company’s refocused go-to-market
strategy for MelaFind®, including its sales and marketing efforts
targeting leading medical dermatologists in the U.S. and
Europe.
Access to the webcast and presentation will be available live
during the conference at 9:30am EST on February 6, 2014 via the
following links:
Live Audio Webcast: MELA Sciences' WebcastPresentation
Slides: MELA Sciences' Corporate Presentation
MELA Sciences will also be participating at the 10th Annual Maui
Derm Conference at the Grand Wailea Hotel, January 26 – 30, 2014.
The conference is designed to increase physicians’ knowledge of
developments in both medical and cosmetic dermatology. MELA will
exhibit four clinical posters at the event as well as host a
MelaFind® workshop on Sunday, January 26. Dr. Monica Scheel, who
recently presented new real-world clinical data at MELA Sciences’
Clinical Advisory meeting at the Winter Clinical Dermatology
Conference – Hawaii® last week, will host the workshop.
Please follow us:
Twitter: @MELASciencesIR or @MelaFindStockTwits:
@MELASciencesIRFacebook: www.facebook.com/MelaFind
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
flagship product is MelaFind®, an FDA, PMA and CE Mark approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. It provides images and data on the
relative disorganization of a lesion's cell structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA
is also exploring new potential uses for its core imaging
technology and algorithms.
MediaMELA Sciences, Inc.Diana Garcia Redruello,
914-591-3783dgarcia@melasciences.comorInvestorsCatalyst
GlobalToni TrigianiDavid
Collins212-924-9800mela@catalyst-ir.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024